Filtered By:
Management: Food and Drug Administration (FDA)
Therapy: Stem Cell Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 140 results found since Jan 2013.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica. 2023 Aug 31. doi: 10.3324/haematol.2023.283509. Online ahead of print.ABSTRACTMelphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone was approved in Europe for use in patients with triple-class refractory relapsed/refractory multiple myeloma (RRMM) with ≥3 prior lines of therapy and without prior autologous stem cell transplantation (ASCT) or with a time to progression >36 months after prior ASCT. The randomized LIGHTHOUSE study (NCT04649060) assessed melflufen plus daratumumab and dexamethasone (melflufen group) versus daratumumab in patients with RRMM...
Source: Haematologica - August 30, 2023 Category: Hematology Authors: Lud ěk Pour Monika Szarejko Jelena Bila Fredrik H Schjesvold Ivan Spicka Vladimir Maisnar Artur Jurczyszyn Zhanet Grudeva-Popova Roman H ájek Ganna Usenko Marcus Thuresson Stefan Norin Sara Jarefors Nicolaas A Bakker Paul G Richardson Maria-Victoria Mat Source Type: research
Exploring Prognostic Biomarkers of Acute Myeloid Leukemia to Determine Its Most Effective Drugs from the FDA-Approved List through Molecular Docking and Dynamic Simulation
This study used bioinformatics approaches for identifying hub genes and pathways associated with AML development to uncover potential molecular mechanisms. The expression profiles of RNA-Seq datasets, GSE68925 and GSE183817, were retrieved from the Gene Expression Omnibus (GEO) database. These two datasets were analyzed by GREIN to obtain differentially expressed genes (DEGs), which were used for performing the Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, protein-protein interaction (PPI), and survival analysis. The molecular docking and dynamic simulation were performed to identify the most ...
Source: Cell Research - June 26, 2023 Category: Cytology Authors: Md Murshid Alom Md Omar Faruqe Md Khademul Islam Molla Md Motiur Rahman Source Type: research
Scientists use AI to identify likely drug targets in search for Alzheimer ' s cure
Scientists use AI to identify likely drug targets in search for Alzheimer's cure
A team led by a University of Arizona College of Medicine – Tucson scientist harnesses artificial intelligence to trace the path from a healthy brain cell to one afflicted by Alzheimer ' s disease.
Anna C. Christensen
Today
College of Medicine – TucsonRui-Chang_khp-web.jpg
Rui Chang, an associate professor of neurology, is leading a team at the College of Medicine – Tucson that uses artificial intelligence to trace the molecular path of the development of Alzheimer's disease.HealthCollege of Medicine - TucsonDeterminationE...
Source: The University of Arizona: Health - May 15, 2023 Category: Universities & Medical Training Authors: mittank Source Type: research
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
Sci Adv. 2023 May 3;9(18):eadf0108. doi: 10.1126/sciadv.adf0108. Epub 2023 May 3.ABSTRACTImmune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of established tumors, combined with increased survival and reduced cancer-associated bone disease. Pretreatment wi...
Source: Adv Data - May 3, 2023 Category: Epidemiology Authors: Jeremy S Frieling Leticia Tordesillas Xiomar E Bustos Maria Cecilia Ramello Ryan T Bishop Junior E Cianne Sebastian A Snedal Tao Li Chen Hao Lo Janis de la Iglesia Emiliano Roselli Ismah ène Benzaïd Xuefeng Wang Youngchul Kim Conor C Lynch Daniel Abate- Source Type: research
UCLA-led study uses base editing to correct mutation that causes rare immune deficiency
Key takeawaysA condition called CD3 delta SCID is caused by a mutation in the CD3D gene, which prevents the production of the CD3 delta protein that is needed for the normal development of T cells from blood stem cells.UCLA researchers showed that a new genome editing technique called base editing can correct the mutation that causes CD3 delta SCID in blood stem cells and restore their ability to produce T cells.Base editing is an ultraprecise form of genome editing that enables scientists to correct single-letter mutations in DNA.A new UCLA-led study suggests that advanced genome editing technology could be used as a ...
Source: UCLA Newsroom: Health Sciences - March 20, 2023 Category: Universities & Medical Training Source Type: news
Top advances of the year: Neuro-oncology
Cancer. 2023 Feb 24. doi: 10.1002/cncr.34711. Online ahead of print.ABSTRACTManagement of brain tumors has been challenging given the limited therapeutic options and disabling morbidities associated with central nervous system (CNS) dysfunction. This review focuses on recent developments in the field, with an emphasis on clinical management. The growing clinical trials landscape reflects advanced insights into cancer immunology and genomics and the need to address molecular and clinical heterogeneity. Recent phase 3 trials investigating anti-PD-1 immunotherapies, particularly nivolumab, have failed to demonstrate improved ...
Source: Cancer Control - February 24, 2023 Category: Cancer & Oncology Authors: Mary M Barden Antonio M Omuro Source Type: research
Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options
World J Gastroenterol. 2022 Dec 28;28(48):6827-6845. doi: 10.3748/wjg.v28.i48.6827.ABSTRACTPancreatic cancer (PC) is the third-leading cause of cancer deaths. The overall 5-year survival rate of PC is 9%, and this rate for metastatic PC is below 3%. However, the PC-induced death cases will increase about 2-fold by 2060. Many factors such as genetic and environmental factors and metabolic diseases can drive PC development and progression. The most common type of PC in the clinic is pancreatic ductal adenocarcinoma, comprising approximately 90% of PC cases. Multiple pathogenic processes including but not limited to inflammat...
Source: World Journal of Gastroenterology : WJG - January 12, 2023 Category: Gastroenterology Authors: Chun-Ye Zhang Shuai Liu Ming Yang Source Type: research
